Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00812175 · ClinicalTrials.gov registry record
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 3,371
- Enrollment target
NCT00812175: Completed study, sponsored by Bayer.
NCT00812175 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 3,371 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00812175 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 3,371 participants
- Enrollment target
Study Summary
In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.
Interventions
- DRUG Sorafenib (Nexavar, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,371 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-04 |
What the finished NCT00812175 record still lists
NCT00812175 is an observational study that tracks outcomes without assigning an intervention. Its 3,371 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib (Nexavar, BAY43-9006) is the first listed.
NCT00812175 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00812175 about?
NCT00812175 is a clinical study titled "Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib". In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.
What is the current status of trial NCT00812175?
This trial is currently completed. The enrollment target is 3,371 participants. The study started on 2009-01. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00812175?
The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00812175?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia